Sol-Gel Technologies Ltd. (SLGL)


-0.14 (-2.64%)
Symbol SLGL
Price $5.16
Beta 1.284
Volume Avg. 0.01M
Market Cap 119.348M
Shares () -
52 Week Range 3.94-8.082
1y Target Est -
DCF Unlevered SLGL DCF ->
DCF Levered SLGL LDCF ->
ROE 12.97% Buy
ROA 12.31% Buy
Operating Margin -
Debt / Equity 8.03% Neutral
P/E 25.80 Strong Buy
P/B 2.51 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest SLGL news

Dr. Alon Seri-Levy
NASDAQ Global Market

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.